Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Peldesine (BCX 34) 是一种有效的、竞争性的、可逆的和口服活性的嘌呤核苷磷酸化酶抑制剂。 Peldesine 抑制 T 细胞增殖,IC50 为 800 nM。 Peldesine 可用于皮肤 T 细胞淋巴瘤、牛皮癣和 HIV 感染的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,310 | 现货 | ||
5 mg | ¥ 2,890 | 现货 | ||
10 mg | ¥ 4,330 | 现货 | ||
25 mg | ¥ 6,890 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,600 | 现货 | ||
500 mg | ¥ 25,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,180 | 现货 |
产品描述 | Peldesine (BCX 34) is an effective, competitive, reversible, and orally active inhibitor of purine nucleoside phosphorylase. Peldesine inhibits T-cell proliferation with an IC50 of 800 nM. Peldesine can be used in research on cutaneous T-cell lymphoma, psoriasis and HIV infection. |
靶点活性 | Human RBC PNP:36 nM , Human T-cell proliferation:800 nM , Rat RBC PNP:5 nM , Mouse RBC PNP:32 nM |
体外活性 | The IC50s are 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell purine nucleoside phosphorylase, respectively. In Jurkat cells, Peldesine (BCX 34; 0-50 µM; 72 hours) inhibits the T-cell proliferation completely at a concentration of less than 10 μM, in the presence of dGuo (10 μM). In contrast, the B-cell proliferation is not affected by Peldesine[1]. |
体内活性 | Peldesine is orally active in elevating plasma inosine in rats (2-fold at 30 mg/kg), in suppressing ex vivo RBC PNP activity in rats (98% at 3 h. 100 mg/kg), and in suppressing ex vivo skin PNP in mice (39% at 3 h, 100 mg/kg). Oral bioavailability of Peldesine in rats is 76%[2]. |
别名 | BCX 34 |
分子量 | 241.25 |
分子式 | C12H11N5O |
CAS No. | 133432-71-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 195 mg/mL (808.29 mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.1451 mL | 20.7254 mL | 41.4508 mL | 103.6269 mL |
5 mM | 0.829 mL | 4.1451 mL | 8.2902 mL | 20.7254 mL | |
10 mM | 0.4145 mL | 2.0725 mL | 4.1451 mL | 10.3627 mL | |
20 mM | 0.2073 mL | 1.0363 mL | 2.0725 mL | 5.1813 mL | |
50 mM | 0.0829 mL | 0.4145 mL | 0.829 mL | 2.0725 mL | |
100 mM | 0.0415 mL | 0.2073 mL | 0.4145 mL | 1.0363 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Peldesine 133432-71-0 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome HIV Protease Nucleoside Antimetabolite/Analog Inhibitor inhibit PNP inosine dGuo HIV Nucleoside psoriasis phosphorylase Human immunodeficiency virus lymphoma IL-2 T-cell BCX 34 BCX-34 immunosuppressive BCX34 inhibitor